India's First Dengue Vaccine QDENGA: Price, Availability & Everything You Need to Know
India approves its first dengue vaccine. Who should take it, how effective it is, and when will it hit the market?
Quick Highlights
Particulars
Details
Vaccine Name
QDENGA (TAK-003)
Manufacturer
Takeda Pharmaceutical (Japan)
Approval Status
Approved by DCGI India ✅
Target Age Group
4 to 60 years
Dosage
2 doses, 3 months apart
Protection
All 4 dengue serotypes
Pre-screening
Not required (no blood test needed)
Efficacy (12 months)
80.2%
Hospitalisation Prevention
90.4%
Expected Launch
First half of 2027
Estimated Price
₹3,000 – ₹12,000 per dose
Status
Approved ✅
Opportunity Overview
Particular
Details
Vaccine Name
QDENGA (TAK-003)
Manufacturer
Takeda Pharmaceutical, Japan
Regulator
DCGI (India)
Type
Live-attenuated tetravalent vaccine
Target Population
4-60 years
Approval Date
July 2026
About the Vaccine
QDENGA is a live-attenuated tetravalent vaccine designed to protect against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO) , approved Japanese pharmaceutical company Takeda's dengue vaccine. This marks India's first-ever dengue vaccine.
The approval comes at a critical time, as dengue cases have surged dramatically across the country. Over the past two decades, India has witnessed an 11-fold increase in dengue cases. India now bears nearly one-third of the global dengue burden.
"Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally." — Mahender Nayak, Head of Intercontinental Markets, Takeda
Vaccine Features
Feature
Details
Type
Live-attenuated tetravalent vaccine
Protection
All 4 dengue virus serotypes
Dosage
2 doses, 3 months apart
Administration
0.5 mL subcutaneous injection
Pre-vaccination testing
Not required
QDENGA vs Dengvaxia (Sanofi)
Feature
QDENGA (Takeda)
Dengvaxia (Sanofi)
Pre-screening
Not required
Required (prior dengue infection)
Approval in India
Yes ✅
No ❌
Age group
4-60 years
9-45 years (with prior infection)
Effectiveness
QDENGA received approval based on extensive clinical trials involving over 28,000 participants across 19 Phase I, II, and III trials.
Parameter
Result
Efficacy against dengue (12 months)
80.2%
Efficacy against hospitalisation (18 months)
90.4%
Hospitalisation prevention (4.5 years)
84.1%
Protection against confirmed dengue
~61%
Sustained protection
Up to 7 years
"QDENGA can help reduce disease severity and hospitalizations, but it is unlikely to prevent outbreaks as long as the mosquito vector continues to circulate." — Divya K.S., Infectious Diseases Specialist, Apollo Hospitals
Dosage & Administration
Criteria
Details
Age Group
4 to 60 years
Prior Dengue Infection
Not required
Pre-vaccination Screening
Not needed
Doses
2 doses of 0.5 mL each
Interval
3 months gap
Route
Subcutaneous injection
Price (Estimated)
Following DCGI approval, the vaccine will first become available in private healthcare settings. The price may decrease if included in government immunisation programmes.
Estimate
Amount (per dose)
Estimated price range
₹3,000 – ₹12,000
Official price
Not yet announced
Note
Estimated prices; official announcement pending
"Experts expect the cost to decline in the coming years as domestic production increases."
Availability Timeline
Timeline
Detail
DCGI Approval
July 2026 ✅
Expected Market Launch
First half of 2027
Production Capacity
50 million doses/year (Biological E partnership)
Global Availability
Already in 43 countries
India-Based Manufacturing Partnership
In 2024, Takeda partnered with Hyderabad-based vaccine manufacturer Biological E. Biological E will produce 50 million doses annually. Takeda's global target: 100 million doses/year by 2030.
Official not announced, estimated ₹3,000-12,000 per dose
When will it be available?
Expected first half of 2027
Will it be in government programmes?
Not yet clear; will start in private market
CareerFlora Expert Insight
The approval of QDENGA in India marks a historic milestone in dengue control. This vaccine protects against all four serotypes and requires no pre-screening, making it ideal for mass vaccination programmes.
However, experts emphasize that this vaccine will not stop outbreaks as long as the mosquito vector continues to circulate. Therefore:
✅ Most important – mosquito control (mosquito nets, repellents, eliminating stagnant water)
✅ Best for high-risk groups – children, elderly, and people in endemic regions
✅ Initial high price – may come down with domestic production and government procurement
For now, QDENGA represents a powerful tool in India's fight against dengue, but it is not a silver bullet. The vaccine will help reduce severe disease and hospitalisation, but prevention through mosquito control remains paramount.
Career Expert & Researcher. Dedicated to bringing you the most authentic and verified updates on global scholarships, internships, and career opportunities to help you stay ahead.
We use cookies to enhance your browsing experience, serve personalized ads, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
Read More.
